What is the appropriate treatment for Paget disease of bone in a 65-year-old man with prostate cancer?

Treatment of Paget Disease in a 65-Year-Old Male with Prostate Cancer

A single 5-mg intravenous infusion of zoledronic acid is the treatment of choice for Paget disease of bone in this patient, provided renal function is adequate (GFR ≥35 mL/min) and vitamin D status is optimized before treatment. 1

Primary Treatment Recommendation

Zoledronic acid demonstrates superior efficacy compared to all other bisphosphonates for Paget disease, achieving:

• Normalization of alkaline phosphatase in 89% of patients (versus 58% with risedronate)
• Sustained remission in 87% at 5-6 years after a single infusion (versus 38% with risedronate)
• More rapid symptom relief and improved quality of life scores maintained throughout follow-up 1

The Endocrine Society Clinical Practice Guideline explicitly states that zoledronic acid's demonstration of "more rapid, more frequent, and much more sustained disease control after a single iv infusion recommends zoledronate in preference to risedronate," and by extension, all other oral agents 1.

Critical Pre-Treatment Considerations

Renal Function Assessment

• Do not administer zoledronic acid if GFR <35 mL/min due to nephrotoxicity risk 1
• This is particularly important in prostate cancer patients who may have compromised renal function from disease or androgen deprivation therapy

Vitamin D Optimization

• Check 25-hydroxyvitamin D levels before treatment
• If <25 nmol/L, supplement with 100,000 units of oral calciferol as a single dose before bisphosphonate administration 1
• Potent bisphosphonates can cause symptomatic hypocalcemia in vitamin D-deficient patients

Calcium and Vitamin D Maintenance

• All patients should receive 1000-2000 IU vitamin D3 daily
• Ensure 1000-1200 mg calcium daily through diet or supplementation (500-1000 mg if dietary intake insufficient) 2

Managing the Acute Phase Response

Approximately 25% of patients experience flu-like illness after zoledronic acid infusion 1. To mitigate this:

• Prophylactic acetaminophen or NSAIDs reduce frequency and severity by approximately 50% 1
• Warn the patient this may occur but typically resolves within a few days
• Monitor for uveitis (occurs in ~1% of patients), which requires prompt ophthalmology referral and resolves with topical steroids 1

Special Consideration: Concurrent Prostate Cancer

The presence of prostate cancer does not contraindicate zoledronic acid for Paget disease 3. However, be aware:

• Bone scintigraphy may show increased uptake from both Paget disease and metastatic disease
• PSMA PET-CT can differentiate between pagetic bone (no PSMA uptake) and prostate cancer metastases (PSMA-avid) 4
• If the patient is on androgen deprivation therapy, he may already be receiving bone-protective agents for cancer treatment-induced bone loss 2

Alternative Options (Second-Line)

If zoledronic acid is contraindicated due to renal impairment:

• Oral risedronate 30 mg daily for 2-3 months (normalizes ALP in 73% of patients) 1
• Oral alendronate 40 mg daily for 6 months (normalizes ALP in 60-70% of patients) 1
• Denosumab may be considered as an off-label option if bisphosphonates are contraindicated, though it only partially corrects pagetic activity 5

Treatment Indications in This Patient

Treatment is indicated if the patient has:

• Bone pain at pagetic sites
• Disease at sites susceptible to complications (skull, weight-bearing bones, areas adjacent to joints)
• Neurological complications from pagetic involvement
• Planned surgery at a pagetic site 6, 7

Monitoring Response

• Measure total alkaline phosphatase (ALP) with liver function tests at baseline and 6 months post-treatment 6
• Patients achieving **P1NP <40 μg/L or total ALP <80 IU/L at 6 months** have >90% likelihood of sustained remission 1
• The 2019 guideline recommends treating symptoms rather than targeting ALP normalization as the primary goal 6

Common Pitfall to Avoid

Do not withhold treatment due to concerns about Ra-223 therapy for potential future prostate cancer bone metastases—there is no contraindication to using zoledronic acid for Paget disease in patients with prostate cancer, and Ra-223 is not contraindicated in Paget disease 3.